logo image
search icon
Age-related Macular Degeneration (AMD) Drugs Market

Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Distribution by Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User and Segment Forecasts, 2024-2031

Report ID : 2854 | Published : 2024-10-15 | Pages: 172 | Format: PDF/EXCEL

Age-related Macular Degeneration (AMD) Drugs Market Size is valued at USD 9.58 Bn in 2023 and is predicted to reach USD 19.77 Bn by the year 2031 at an 9.7% CAGR during the forecast period for 2024-2031.

age related macular

Age-related macular degeneration is a degenerative eye disease commonly occurring after the age of 50, leading to vision loss in the inner area of the visual field. There are two types: dry AMD - degeneration of vision due to gradual thinning of the macula; wet AMD - rapid degeneration through unhealthy growth under the retina. Treatment for AMD is primarily aimed at the wet form with anti-vascular endothelial growth factor (anti-VEGF) therapies, including Eylea (aflibercept), Lucentis (ranibizumab), and new Vabysmo (faricimab). In 2023, the FDA authorized Syfovre, the inaugural medicine for treating dry age-related macular degeneration (AMD).  Syfovre is the first treatment to receive FDA approval, having shown a reduction of around 20% in the progression of blind spots associated with advanced dry macular degeneration over a two-year period.

Major drivers for the AMD drug market include an increasing emphasis on research and development. New formulations and delivery systems are developed to minimize side effects, enhance treatment effectiveness, and enhance compliance by either extending dosing intervals or offering alternative delivery mechanisms. Additionally, novel therapies for wet and dry AMD will propel future market growth by bridging unmet medical needs within the studied patient population.

Competitive Landscape

Some of the Key Players in Age-related Macular Degeneration (AMD) Drugs Market:

  • Regeneron Pharmaceuticals Inc. (US)
  • Bayer AG (Germany)
  • Hoffmann-La Roche AG (Switzerland)
  • Novartis AG (Switzerland)
  • Apellis Pharmaceuticals, Inc. (US)
  • Coherus BioSciences, Inc. (US)
  • Astellas Pharma Inc. (Japan)
  • Biogen (US)
  • STADA Arzneimittel AG (Germany)
  • Formycon AG (Germany)
  • (India)
  • Outlook Therapeutics, Inc. (US)
  • Intas Pharmaceuticals Ltd. (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Chengdu Kanghong Biotech Company (China)
  • Sandoz Group AG (Switzerland)
  • Stealth BioTherapeutics Inc. (US)
  • Ocular Therapeutix, Inc. (US)
  • Opthea Limited, Inc. (Australia)
  • Kodiak Sciences Inc. (US)
  • Innovent Biologics, Inc. (China)
  • Bio-Thera Solution Inc. (China)
  • Alvotech (Iceland)
  • Alteogen Inc. (South Korea)
  • Shanghai Henlius Biotech, Inc. (China)
  • Amgen Inc. (US)
  • Ocumension Therapeutics. (China)
  • Adverum Biotechnologies, Inc. (US)

Market Segmentation:

The age-related Macular Degeneration (AMD) Drugs market is segmented by products, molecules, type of AMD, approval type, end user. By products the market is segmented into lucentis, eylea & eylea HD, vabysmo, syfovre, other products. By molecules market is categorized into ranibizumab, aflibercept, faricimab, pegcetoplan, other molecules. By type of AMD market is categorized into wet AMD, dry AMD. By approval type market is segmented into biologic, biosimilar. By end user the market is categorized into hospitals, specialty centers, and long-term care facilities.

Eylea and Eylea HD Segment is Expected to Drive the Age-related Macular Degeneration (AMD) Drugs Market

The Eylea and Eylea HD segment is a significant driver in the Age-related Macular Degeneration drugs market through its established efficacy, broad acceptance, and continuous innovations that enhance treatment protocols. Through its higher dose (8 mg as opposed to 2 mg), Eylea HD has shown promise in the elongation of treatment intervals, thus making it less burdensome for patients and, therefore, presumably enhancing compliance. Long-term dosing for this kind of drug is part of a strategic approach against competitors like Roche's Vabysmo, which has the benefit of doing once a month. These developments and research into new formulations and delivery systems position Regeneron at the competitive edge in AMD drugs. All these factors ensure Eylea and Eylea HD remain the frontier AMD treatments, driving up market growth and leading to future choices in therapeutics.

Dry AMD is Growing at the Highest Rate in the Age-related Macular Degeneration (AMD) Drugs Market.

The Dry AMD segment is expected to grow considerably in the market for drugs targeted at treating age-related macular degeneration (AMD). Recent FDA approvals, with a strong pipeline of new therapies and growing prevalence, will propel the Dry AMD segment forward. Approvals over 2023 for such key therapies as Pegcetacoplan in Syfovre and Avacincaptad Pegol in IZERVAY indicated the need for effective treatments for dry AMD and infused confidence in the market, attracting still further investment. But finally, promising pipelines in terms of peptide derivatives and gene therapies from companies like Alkeus Pharmaceuticals and Belite Bio bode well for future progress. Dry AMD accounts for almost 90% of all cases of AMD and is increasing with global aging; hence, it is an important segment and encourages pharmaceutical companies to act fast, accelerate new treatments, and ensure big returns.

Regionally, North America Led the Age-related Macular Degeneration (AMD) Drugs Market.

North America leads in this market, largely due to a high incidence rate of AMD, high pharmaceutical R&D capabilities, and multiple available therapies. Regionally, the market is experiencing increased unmet needs, with nearly 200,000 new cases diagnosed each year. Similarly, strong R&D investments are made in North America, and as a result, some major pharmaceutical research-oriented institutes are also present there; for example, the recent approval of biosimilar Enzeevu for treating wet AMD. Apart from this, numerous treatment options are available, including Eylea, Lucentis, Vabysmo, and Syfovre, which places all patients at a developed level of care.

Age-related Macular Degeneration (AMD) Drugs Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 9.58 Bn

Revenue Forecast In 2031

USD 19.77 Bn

Growth Rate CAGR

CAGR of 9.7 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Products, Molecules, Type of AMD, Approval type, End User and By Region

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia

Competitive Landscape

Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, Inc. (US), Coherus BioSciences, Inc. (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China), Sandoz Group AG (Switzerland), Stealth BioTherapeutics Inc.  (US), Ocular Therapeutix, Inc. (US), Opthea Limited, Inc. (Australia), Kodiak Sciences Inc. (US), Innovent Biologics, Inc. (China), Bio-Thera Solution Inc. (China), Alvotech (Iceland), Alteogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), Amgen Inc. (US), Ocumension Therapeutics. (China) and Adverum Biotechnologies, Inc. (US)

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape.                     

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

 

Chapter 1.          Methodology and Scope

1.1.        Research Methodology

1.2.        Research Scope & Assumptions

Chapter 2.          Executive Summary

Chapter 3.          Global Age-related Macular Degeneration (AMD) Drugs Market Snapshot

Chapter 4.          Global Age-related Macular Degeneration (AMD) Drugs Market Variables, Trends & Scope

4.1.        Market Segmentation & Scope

4.2.        Drivers

4.3.        Challenges

4.4.        Trends

4.5.        Investment and Funding Analysis

4.6.        Porter's Five Forces Analysis

4.7.        Incremental Opportunity Analysis (US$ MN), 2024-2031

4.8.        Global Age-related Macular Degeneration (AMD) Drugs Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031

4.9.        Competitive Landscape & Market Share Analysis, By Key Player (2023)

4.10.     Use/impact of AI on Age-related Macular Degeneration (AMD) Drugs Industry Trends

Chapter 5.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 1: By Products, Estimates & Trend Analysis

5.1.        Market Share by Products, 2023 & 2031

5.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Products:

5.2.1.    Lucentis

5.2.2.    Eylea & Eylea HD

5.2.3.    Vabysmo

5.2.4.    Syfovre

5.2.5.    Other Products

Chapter 6.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 2: By Molecules, Estimates & Trend Analysis

6.1.        Market Share by Molecules, 2023 & 2031

6.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Molecules:

6.2.1.    Ranibizumab

6.2.2.    Aflibercept

6.2.3.    Faricimab

6.2.4.    Pegcetoplan

6.2.5.    Other Molecules

Chapter 7.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 3: By Type of AMD, Estimates & Trend Analysis

7.1.        Market Share by Type of AMD, 2023 & 2031

7.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of AMD:

7.2.1.    Wet AMD

7.2.2.    Dry AMD

Chapter 8.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 4: By Approval type, Estimates & Trend Analysis

8.1.        Market Share by Approval type, 2023 & 2031

8.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Approval type:

8.2.1.    Biologic

8.2.2.    Biosimilar

Chapter 9.          Age-related Macular Degeneration (AMD) Drugs Market Segmentation 5: By End Users, Estimates & Trend Analysis

9.1.        Market Share by End Users, 2023 & 2031

9.2.        Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:

9.2.1.    Hospitals

9.2.2.    Specialty Centers

9.2.3.    Long-Term Care Facilities

Chapter 10.        Age-related Macular Degeneration (AMD) Drugs Market Segmentation 6: Regional Estimates & Trend Analysis

10.1.     Global Age-related Macular Degeneration (AMD) Drugs Market, Regional Snapshot 2023 & 2031

10.2.     North America

10.2.1.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.2.1.1.             US

10.2.1.2.             Canada

10.2.2.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.2.3.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.2.4.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.2.5.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.2.6.  North America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

10.3.     Europe

10.3.1.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.3.1.1.             Germany

10.3.1.2.             U.K.

10.3.1.3.             France

10.3.1.4.             Italy

10.3.1.5.             Spain

10.3.1.6.             Rest of Europe

10.3.2.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.3.3.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.3.4.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.3.5.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.3.6.  Europe Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

10.4.     Asia Pacific

10.4.1.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.4.1.1.             India

10.4.1.2.             China

10.4.1.3.             Japan

10.4.1.4.             Australia

10.4.1.5.             South Korea

10.4.1.6.             Hong Kong

10.4.1.7.             Southeast Asia

10.4.1.8.             Rest of Asia Pacific

10.4.2.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.4.3.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.4.4.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.4.5.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By Approval type, 2024-2031

10.4.6.  Asia Pacific Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts By End Users, 2024-2031

10.5.     Latin America

10.5.1.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031

10.5.1.1.             Brazil

10.5.1.2.             Mexico

10.5.1.3.             Rest of Latin America

10.5.2.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.5.3.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.5.4.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.5.5.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.5.6.  Latin America Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

10.6.     Middle East & Africa

10.6.1.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

10.6.1.1.             GCC Countries

10.6.1.2.             Israel

10.6.1.3.             South Africa

10.6.1.4.             Rest of Middle East and Africa

10.6.2.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Products, 2024-2031

10.6.3.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Molecules, 2024-2031

10.6.4.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Type of AMD, 2024-2031

10.6.5.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by Approval type, 2024-2031

10.6.6.  Middle East & Africa Age-related Macular Degeneration (AMD) Drugs Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2024-2031

Chapter 11.        Competitive Landscape

11.1.     Major Mergers and Acquisitions/Strategic Alliances

11.2.     Company Profiles

 

11.2.1.  Regeneron Pharmaceuticals Inc. (US)

11.2.1.1.             Business Overview

11.2.1.2.             Key Product/Service Offerings

11.2.1.3.             Financial Performance

11.2.1.4.             Geographical Presence

11.2.1.5.             Recent Developments with Business Strategy

11.2.2.  Bayer AG (Germany)

11.2.3.  F. Hoffmann-La Roche AG (Switzerland)

11.2.4.  Novartis AG (Switzerland)

11.2.5.  Apellis Pharmaceuticals, Inc. (US)

11.2.6.  Coherus BioSciences, Inc. (US)

11.2.7.  Astellas Pharma Inc. (Japan)

11.2.8.  Biogen (US)

11.2.9.  STADA Arzneimittel AG  (Germany)

11.2.10.              Formycon AG (Germany)

11.2.11.              Biocon. (India)

11.2.12.              Outlook Therapeutics, Inc. (US)

11.2.13.              Intas Pharmaceuticals Ltd. (India)

11.2.14.              Teva Pharmaceutical Industries Ltd. (Israel)

11.2.15.              Chengdu Kanghong Biotech Company (China)

11.2.16.              Sandoz Group AG (Switzerland)

11.2.17.              Stealth BioTherapeutics Inc.  (US)

11.2.18.              Ocular Therapeutix, Inc. (US)

11.2.19.              Opthea Limited, Inc. (Australia)

11.2.20.              Kodiak Sciences Inc. (US)

11.2.21.              Innovent Biologics, Inc. (China)

11.2.22.              Bio-Thera Solution Inc. (China)

11.2.23.              Alvotech (Iceland)

11.2.24.              Alteogen Inc. (South Korea)

11.2.25.              Shanghai Henlius Biotech, Inc. (China)

11.2.26.              Amgen Inc. (US)

11.2.27.              Ocumension Therapeutics. (China)

11.2.28.              Adverum Biotechnologies, Inc. (US)

11.2.29.              Other Prominent Players

Segmentation of Age-related Macular Degeneration (AMD) Drugs Market -

Age-related Macular Degeneration (AMD) Drugs Market by Products -

  • Lucentis
  • Eylea & Eylea HD
  • Vabysmo
  • Syfovre
  • Other Products

age related macular

Age-related Macular Degeneration (AMD) Drugs Market by Molecules -

  • Ranibizumab
  • Aflibercept
  • Faricimab
  • Pegcetoplan
  • Other Molecules

Age-related Macular Degeneration (AMD) Drugs Market by Type of AMD -

  • Wet AMD
  • Dry AMD

Age-related Macular Degeneration (AMD) Drugs Market by Type of Approval type -

  • Biologic
  • Biosimilar

Age-related Macular Degeneration (AMD) Drugs Market by End User -

  • Hospitals
  • Specialty Centers
  • Long-Term Care Facilities

Age-related Macular Degeneration (AMD) Drugs Market by Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Age-related Macular Degeneration (AMD) Drugs Market?

Age-related Macular Degeneration (AMD) Drugs Market is expected to grow at an 9.7% CAGR during the forecast period for 2024-2031.

Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, In

The Age-related Macular Degeneration (AMD) Drugs Market includes five segments Products, Molecules, Type of AMD, Approval type, and End-User.

North American region is leading the Age-related Macular Degeneration (AMD) Drugs Market.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach